|
|
|
|
|
Highlights from the American Urological Association Annual Meeting |
|
|
|
| The Society of Urologic Oncology Whitmore Lecture
|
| Peter Carroll, MD, MPH
|
| This year’s Whitmore Lecture at the AUA virtual annual meeting’s Society of Urologic Oncology afternoon session was delivered by Peter Carroll from UCSF. Dr. Carroll was a urologic oncology fellow under Dr. Whitmore at Memorial Sloan Kettering Cancer Center (MSKCC) in 1986 and throughout his talk provided several lessons learned, not just from his time at MSKCC, but also throughout his career.
|
|
|
|
|
|
| Racial Disparity in The Utilization of New Therapies for Advanced Prostate Cancer
|
| Ali Mouzannar, MD
|
| In a podium presentation at the American Urological Association (AUA) Virtual Annual Meeting, Ali Mouzannar assessed whether there was disparity in the utilization of immunotherapy in the treatment of black and Hispanic patients with mCRPC.
|
|
|
|
|
|
| Impact of Darolutamide on Local Symptoms in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
|
| Neal Shore, MD, FACS
|
| In a podium presentation at the American Urologic Association Annual Meeting, Neal Shore assessed the relationship between prostate-specific antigen (PSA) response and urinary and bowel adverse events (AEs), time to deterioration in quality of life (QoL), and prostate cancer (PC)–related invasive procedures in ARAMIS.
|
|
|
|
|
|
| Association Between Disease Indication and Steroid Use and Mineralocorticoid-Related Toxicity of Abiraterone Acetate in Patients With Advanced Prostate Cancer: A Meta-Analysis of Randomized Control Trials |
| Mary Hall, MD |
| In this presentation, Mary Hall examines the available evidence regarding the cardiotoxicity of abiraterone acetate via meta-analysis, focusing on mechanistically related side-effects and differences based on disease indication and trial design. |
|
|
|
|
|
|
|
|
|
|
| Efficacy of Physician's Choice of Enzalutamide or Abiraterone in the Control Arm of the PROfound Study |
| Fred Saad, MD, FRCS |
| Fred Saad presents an exploratory analysis of the efficacy of olaparib versus either abiraterone or enzalutamide, given a potential difference in the efficacy of NHA sequencing. Dr. Saad concluded that this exploratory analysis of the PROfound trial demonstrates improved outcomes of olaparib compared to both abiraterone and enzalutamide, without meaningful differences in outcomes in the control arm on the basis of which NHA was used. Further, he emphasized that sequential use of NHA appears to have limited benefit. |
|
|
|
|
|
| Prostate-Specific Antigen Kinetics in Patients With Advanced Prostate Cancer Treated With Apalutamide: Results from the TITAN and SPARTAN Studies
|
| Kim Chi, MD
|
| Kim Chi presented a post hoc analysis of prostate-specific antigen (PSA) kinetics in patients enrolled in the TITAN and SPARTAN trials. Patients with advanced PC, whether mCSPC or nmCRPC, who received apalutamide +ADT demonstrated rapid PSA declines that continued over time. There was a high rate of patients with PSA90 and with PSA≤0.2 ng/mL responses, with a majority of patients reaching PSA90 by 12 months. Those patients who had PSA90 and/or PSA nadir of ≤0.2 ng/mL had improved long-term oncologic outcomes.
|
|
|
|
|
|
| Defining Castration Sensitivity in Metastatic and Nonmetastatic Prostate Cancer
|
| Daniel Lin, MD
|
| Daniel Lin explores the question of defining castration sensitivity in advanced prostate cancer. Dr. Lin began by discussing key considerations in our approach to administering androgen deprivation therapy, namely choosing between GnRH agonists or antagonists. These include potential differences in efficacy, safety, and administration.
|
|
|
|
|
|
| Advances in Nonmetastatic Castration-Resistant Prostate Cancer
|
| David Penson, MD, MPH, MMHC
|
| In a plenary session entitled “Advances in Prostate Cancer: Androgen Deprivation Therapy Across the Disease Continuum” held in conjunction with the American Urologic Association Virtual Annual Meeting, David Penson explored advances in nonmetastatic castration-resistant prostate cancer (nmCRPC).
|
|
|
|
|
|
| Advances in Metastatic Hormone-Sensitive Prostate Cancer/Metastatic Castration-Naive Prostate Cancer |
| Alicia Morgans, MD, MPH |
| Alicia Morgans explored the role of systemic treatment intensification in metastatic castration sensitive prostate cancer (mCPSC). She concludes that treatment intensification with either docetaxel or an androgen receptor targeting agent is the standard of care for patients with mCSPC. The choice among these agents depends on quality of life and patient preferences in the context of shared decision-making. |
|
|
|
|
|
|
|
|
|
|
| Practical Clinical Applications for AR Inhibitor Therapy |
| Alicia Morgans, MD, MPH, Daniel Lin, MD, and David Penson, MD, MPH, MMHC |
| To close the plenary session entitled “Advances in Prostate Cancer: Androgen Deprivation Therapy Across the Disease Continuum” held in conjunction with the American Urologic Association Annual Meeting this evening, Dr. Dan Lin hosted a discussion of pertinent clinical questions along with Dr. Alicia Morgans and Dr. David Penson. In this session, Dr. Lin had laid out the landscape of nmCRPC and mCSPC while Drs. Penson and Morgans highlighted novel treatment approaches for each of these disease states, respectively. |
|
|
|
|
|
| What's New in Biomarkers? |
| Peter Black, MD, FACS, FRCSC |
| The Society of Urologic Oncology session at the 2021 Virtual AUA annual meeting’s bladder cancer session included a presentation by Peter Black discussing what is new for biomarkers in bladder cancer. Dr. Black highlighted that there are different types of biomarkers based on the disease state of interest. |
|
|
|
|
|
| Controversies in the Management of High-Risk Prostate Cancer
|
| Kelvin A. Moses, MD, Ph.D.
|
| In this presentation Kelvin Moses, addresses controversies in the management of high-risk prostate cancer. Dr. Moses emphasized that high-risk disease represents 15% of patients diagnosed with localized prostate cancer and early identification of high-risk characteristics and the extent of disease may allow for tailored therapy. However, most will benefit from a multi-modal approach.
|
|
|
|
|
|
| Design the High-Risk Localized Prostate Cancer Trial: Defining the Endpoints |
| Ronald Chen, MD, MPH |
| Ronald Chen addressed the question of designing the ideal randomized controlled trial in high-risk localized prostate cancer at the American Urological Association's 2021 Annual meeting. Dr. Chen emphasized the need for high-quality data comparing radical prostate and radiotherapy in high-risk prostate cancer. Carefully designed randomized controlled trials and non-randomized prospective studies can provide important high-quality evidence. |
|
|
|
|
|
|
|
| To view our full coverage of the 2021 AUA Annual Meeting, visit the Conference Coverage section on UroToday.com |
|
|
|
|
|
 |
|
|
|
|
